Nisa Investment Advisors LLC continued to hold its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,400 shares of the company’s stock at the end of the second quarter. Nisa Investment Advisors LLC owned approximately 0.08% of Anika Therapeutics worth $612,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC boosted its position in shares of Anika Therapeutics by 165.8% in the first quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock worth $13,434,000 after buying an additional 187,400 shares in the last quarter. Bogle Investment Management L P DE boosted its position in shares of Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock worth $4,962,000 after buying an additional 60,087 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Anika Therapeutics by 308.7% in the first quarter. Fisher Asset Management LLC now owns 57,719 shares of the company’s stock worth $2,792,000 after buying an additional 43,595 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of Anika Therapeutics by 965.7% in the first quarter. Panagora Asset Management Inc. now owns 30,234 shares of the company’s stock worth $1,352,000 after buying an additional 27,397 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Anika Therapeutics by 17.4% in the first quarter. Acadian Asset Management LLC now owns 173,771 shares of the company’s stock worth $7,771,000 after buying an additional 25,727 shares in the last quarter. Institutional investors own 77.85% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 0.19% during midday trading on Friday, reaching $47.37. The company had a trading volume of 133,627 shares. Anika Therapeutics Inc. has a 12-month low of $30.93 and a 12-month high of $54.96. The company has a 50-day moving average of $48.76 and a 200-day moving average of $47.77. The stock has a market capitalization of $699.99 million, a PE ratio of 20.68 and a beta of 1.50.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Wednesday, July 27th. The company reported $0.57 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.13. The business had revenue of $26.60 million for the quarter, compared to analysts’ expectations of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. The business’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS. On average, analysts predict that Anika Therapeutics Inc. will post $2.00 EPS for the current fiscal year.

Separately, Zacks Investment Research upgraded Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a report on Monday, August 1st.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.